Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement activation by cold agglutinins.

M Kirschfink1, H Fritze, D Roelcke

  • 1Institute of Immunology, University of Heidelberg, FRG.

Vox Sanguinis
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local complement activation in aqueous humor in patients with age-related macular degeneration.

Eye (London, England)·2017
Same author

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Clinical and experimental immunology·2016
Same author

Dissection of CD20 regulation in lymphoma using RNAi.

Leukemia·2016
Same author

Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Complement profile in neonates of different gestational ages.

Scandinavian journal of immunology·2014
Same author

Microfungal species composition and fungal biomass in a coniferous forest soil polluted by alkaline deposition.

Microbial ecology·2013

Human IgM cold agglutinins (CA) show varied complement activation. Anti-I CA may enhance hemolysis by interacting with C8 binding protein, unlike other CA specificities, highlighting homologous restriction in complement-mediated lysis.

Area of Science:

  • Immunology
  • Hematology

Background:

  • Cold agglutinins (CA) are autoantibodies that bind red blood cells (RBCs) at low temperatures.
  • IgM cold agglutinins are implicated in cold agglutinin disease, a form of autoimmune hemolytic anemia.

Purpose of the Study:

  • To investigate the complement-activating capacity of different specificities of human IgM cold agglutinins (anti-I, anti-i, anti-Pr).
  • To explore the mechanisms underlying complement-mediated hemolysis induced by these antibodies.

Main Methods:

  • Purified monoclonal human IgM cold agglutinins were incubated with human RBCs.
  • Complement activation was assessed by measuring C1 fixation, C3 deposition, and hemolysis using homologous human serum.
  • Red blood cells sensitized with cold agglutinins were also exposed to heterologous complement (rabbit and rat serum).

Related Experiment Videos

Main Results:

  • Significant differences in hemolytic efficiency were observed among anti-I, anti-i, and anti-Pr cold agglutinins.
  • Complement activation via the classical pathway (C1 fixation and C3 deposition) occurred with all tested CA specificities.
  • Hemolysis did not directly correlate with antibody or C3 deposition levels, suggesting other regulatory factors are involved.
  • Anti-I cold agglutinin-induced hemolysis may be influenced by interaction with C8 binding protein, potentially hindering its regulatory function.
  • Heterologous complement (rabbit and rat serum) was more efficient in lysing cold agglutinin-sensitized RBCs than homologous human serum, indicating the importance of homologous restriction.

Conclusions:

  • The hemolytic efficiency of IgM cold agglutinins is specific and not solely dependent on antibody or C3 binding levels.
  • Interaction with regulatory proteins like C8 binding protein may play a role in anti-I mediated hemolysis.
  • Homologous restriction significantly limits complement-mediated lysis in human serum, protecting autologous red blood cells.